---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-009939"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:53:54.220388+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences files $300M shelf registration and enters ATM sales agreement with Leerink Partners

## Summary
- Filed Form S-3 to register up to $300M of common stock, preferred, debt, warrants, and units.
- Entered into ATM agreement with Leerink Partners for at-the-market sales of common stock.
- Pays Leerink 3.0% commission on gross proceeds; no minimum sales obligation.
- Sales may occur on Nasdaq or other trading markets; Company can suspend or terminate.

## SEC filing metadata
- accession: 0001140361-25-009939
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000114036125009939/0001140361-25-009939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000114036125009939/ny20045827x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-009939
- JSON: https://secwatch.observer/filing/0001140361-25-009939.json
- Plain text: https://secwatch.observer/filing/0001140361-25-009939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.